Completed PHASE2/PHASE3 INTERVENTIONAL 2-arm NCT00418028

Standard Versus Continuous Capecitabine in Advanced Breast Cancer

Randomized Phase II Trial of Continuous Versus Standard Capecitabine in Advanced Breast Cancer.

Sponsor: Complexo Hospitalario Universitario de A Coruña

Updated 9 times since 2017 Last updated: Feb 21, 2019 Started: Sep 30, 2005 Primary completion: Dec 31, 2011 Completion: Jan 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT00418028, this PHASE2/PHASE3 trial focuses on Metastatic Breast Cancer and remains completed. Sponsored by Complexo Hospitalario Universitario de A Coruña, it has been updated 9 times since 2005, reflecting limited change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

9 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE2/PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE2/PHASE3

Phase: PHASE2_PHASE3 → PHASE2/PHASE3
Jan 2023 — Jul 2024 [monthly]

Completed PHASE2_PHASE3
Dec 2022 — Jan 2023 [monthly]

Completed PHASE2_PHASE3
Jan 2021 — Dec 2022 [monthly]

Completed PHASE2_PHASE3

▶ Show 4 earlier versions

Mar 2019 — Jan 2021 [monthly]

Completed PHASE2_PHASE3
Jun 2018 — Mar 2019 [monthly]

Completed PHASE2_PHASE3
Jan 2018 — Jun 2018 [monthly]

Completed PHASE2_PHASE3

Status: Unknown Status → Completed
Jan 2017 — Jan 2018 [monthly]

Unknown Status PHASE2_PHASE3

First recorded

Sep 2005

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Complexo Hospitalario Universitario de A Coruña
Hospital San Carlos, Madrid

Data source: Hospital San Carlos, Madrid

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Madrid, Spain